Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.39 |
| ▸ | CCR2 | P41597 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683395 | 0.91 | CCR1 (0.40) | CCR1CCR2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL6365285 | 0.82 | KDM1A (0.39) | CCR1CCR2KDM1AKDM1BSMN1; SMN2 | |
| SCHEMBL8560583 | 0.80 | KMT2A (0.53) | OPRM1ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL8560584 | 0.80 | KMT2A (0.53) | OPRM1ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL31176510 | 0.80 | FPR2 (0.30) | OPRM1ROCK2 | |
| SCHEMBL17085728 | 0.79 | CCR1 (0.38) | CCR1CCR2OPRM1ALDH1A1TSHR | |
| SCHEMBL17080097 | 0.79 | CCR1 (0.42) | CCR1CCR2KDM1ASMN1; SMN2MAPT | |
| SCHEMBL4683544 | 0.78 | CCR1 (0.42) | CCR1CCR2ALDH1A1HPGDTSHR | |
| SCHEMBL27469422 | 0.77 | ROCK2 (0.36) | ROCK2 | |
| SCHEMBL6361948 | 0.77 | FPR2 (0.48) | CCR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002080853-A2 | FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | TFPI, F11, F12 | CCR1 3879/4885CCR2 4483/4885OPRM1 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.